<DOC>
	<DOCNO>NCT02197104</DOCNO>
	<brief_summary>The objective study determine citocoline effective balance abnormality stabilize cognitive decline patient fragile X-associated tremor ataxia syndrome . The study test 1000mg twice daily citocoline 12 month open label pilot study , study visit baseline , 3 , 6 , 12 month .</brief_summary>
	<brief_title>Citocoline Treatment FXTAS</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Tremor</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Clinical diagnosis FXTAS Serum creatine kinase , complete metabolic panel , complete blood count , liver function test , renal function test , platelet EKG within normal limit Legal incapacity limit legal capacity Presence severe renal disease ( BUN 50 % great normal creatinine clearance &lt; 60 mL/min ) hepatic disease . Abnormal creatine kinase and/or platelet count past 6 month ( determine lab report obtain primary care physician conduct baseline ) . Women childbearing potential pregnant time screen use adequate protection participation study . Allergy/sensitivity drug formulation . Concurrent participation another clinical study . Active substance use dependence . Serious illness ( require systematic treatment/or hospitalization ) subject either complete therapy clinically stable therapy , opinion site investigator , least 60 day prior study entry . Inability unwillingness subject legal guardian/representative give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>